Brendan M. Everett, MD, MPH

Brigham and Women’s Hospital, United States

Disclosure information not submitted.

Presentation(s):

• The risk of cardiovascular (CV) events after initiation of SGLT2i, GLP-1RA, DPP4i, or SUs in patients with T2D and low-to-moderate CV risk

  Wednesday, August 28, 2024
  9:00 AM – 9:15 AM CEST

• Head-to-head Comparison of Dapagliflozin vs Empagliflozin: Cardiovascular and Safety Events

  Wednesday, August 28, 2024
  9:45 AM – 10:00 AM CEST